In 2023, tuberculosis was again the top infectious disease killer on the planet, having temporarily been overtaken by COVID-19. Even so, investment in TB research is far below what United Nations agencies estimate is needed. Catherine Tomlinson unpacks a new report on global TB research funding, zooming in on the situation in South Africa.
While there are nine experimental tuberculosis (TB) vaccines in advanced trials, the vaccine pipeline beyond those nine prospects is relatively depleted. Adele Baleta reports on this and much more from the virtual Global TB Vaccine Forum held last week.
It is a hundred years since the BCG vaccine, the only registered vaccine proven to offer some protection against tuberculosis (TB), was first used in people. Now researchers in South Africa are at the forefront of clinical trials testing experimental new TB vaccines. Adele Baleta reports.
